Pharmaceutical giant Sanofi (SNY +1.46%) and biotech Regeneron (REGN 0.66%) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (AMGN +1.43%) and Pfizer's (PFE +1.71%) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
